Hiromi Kumon

Hiromi Kumon

Auto-generated profile, based on publicly available information

Hiromi Kumon

Innovation Center Okayama for Nanobio-Targeted Therapy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MAMotoo Araki
Motoo Araki
RKReiko Kariyama
Reiko Kariyama
KMKoichi Monden
Koichi Monden
MTMasaya Tsugawa
Masaya Tsugawa
HKHiromi Kumon
Hiromi Kumon

1 November 2000 in BJU International
Verified
Journal Article
Closed access
PDF file
YYY. Yamamoto
Y. Yamamoto
YNY. Nasu
Y. Nasu
TST. Saika
T. Saika
TAT. Akaeda
T. Akaeda
TTT. Tsushima
T. Tsushima
HKH. Kumon
H. Kumon

6 December 2012 in Journal of Radioanalytical and Nuclear Chemistry
Verified
Journal Article
Open access
PDF file
TTTeruaki Toyota
Teruaki Toyota
THTadashi Hanafusa
Tadashi Hanafusa
TOTakashi Oda
Takashi Oda
IKIwane Koumura
Iwane Koumura
TSTakanori Sasaki
Takanori Sasaki
TOToshiro Ono
Toshiro Ono
Ion exchange is a simple and efficient method for separating no-carrier-added 64Cu from an irradiated Ni target. We developed a semi-automated two-round 64Cu separation system equipped with a strong-base anion exchange resin column. We first verified the efficiency of the system using a non-radioactive substitute consisting of 25 mg of Ni and 127 ng of Cu, and confirmed that Cu was completely eluted at the second round of the separation step. After the bombardment, separation of 64Cu from the Ni target was achieved with high radiochemical purity. 64Cu produced and separated in this study had an extremely low level of Ni impurity. It could be used for labeling monoclonal antibodies for antibody positron emission tomography imaging and synthesizing radiopharmaceuticals.

24 June 2020 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
ETEmi Tanaka
Emi Tanaka
DUDaisuke Uchida
Daisuke Uchida
HSHidenori Shiraha
Hidenori Shiraha
HKHironari Kato
Hironari Kato
AOAtsushi Ohyama
Atsushi Ohyama
HOHiroyuki Okada
Hiroyuki Okada
Background: We previously demonstrated that the reduced expression in immortalized cells (REIC)/dikkopf-3 (Dkk-3) gene was downregulated in various malignant tumors, and that an adenovirus vector carrying the REIC/Dkk-3 gene, termed Ad-REIC induced cancer-selective apoptosis in pancreatic cancer and hepatocellular carcinoma. Objective: In this study, we examined the therapeutic effects of Ad-REIC in biliary cancer using a second- generation Ad-REIC (Ad-SGE-REIC). Methods: Human biliary cancer cell lines (G-415, TFK-1) were used in this study. The cell viability and apoptotic effect of Ad-SGE-REIC were assessed in vitro using an MTT assay and Hoechst staining. The anti-tumor effect in vivo was assessed in a mouse xenograft model. We also assessed the therapeutic effects of Ad-SGE-REIC therapy with cisplatin. Cell signaling was assessed by Western blotting. Results: Ad-SGE-REIC reduced cell viability, and induced apoptosis in biliary cancer cell lines via the activation of the c-Jun N-terminal kinase pathway. Ad-SGE-REIC also inhibited tumor growth in a mouse xenograft model. This effect was further enhanced in combination with cisplatin. Conclusions: Ad-SGE-REIC induced apoptosis and inhibited tumor growth in biliary cancer cells. REIC/Dkk-3 gene therapy using Ad-SGE-REIC is an attractive therapeutic tool for biliary cancer.